Literature DB >> 21244392

Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population.

Choong-Chor Chang1, Chun-Lai Too, Shahnaz Murad, Suraiya Hani Hussein.   

Abstract

BACKGROUND: Carbamazepine (CBZ), a frequently used anticonvulsant drug, is one of the most common causes of life-threatening cutaneous adverse drug reactions such as toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS). Recent studies have revealed a strong association between HLA-B*1502 and CBZ-induced TEN/SJS in the Taiwan Han Chinese population.
OBJECTIVES: This study is aimed to investigate the association between human leucocyte antigens (HLA) and CBZ-induced TEN/SJS in the multi-ethnic Malaysian population.
METHODS: A sample of 21 unrelated patients with CBZ-induced TEN/SJS and 300 race-matched, healthy controls were genotyped for HLA-A, -B and -DR using polymerase chain reaction (PCR). Allele frequencies were compared.
RESULTS: HLA-B*1502 was present in 75.0% (12/16) of Malay patients with CBZ-induced TEN/SJS but in only 15.7% (47/300) of normal controls (odds ratio 16.15, 95% confidence interval 4.57-62.4; corrected P-value  = 7.87 × 10(-6) ), which suggests a strong association between HLA and CBZ-induced TEN/SJS. Additionally, HLA-B*1502 was found in all three Chinese and two Indian patients. Existing data show that frequencies of the HLA-B*1502 allele are generally much higher in Asian populations than in White European populations, which explains the higher incidences of SJS and TEN in Asian countries.
CONCLUSIONS: HLA-B*1502 is strongly associated with CBZ-induced TEN/SJS in the Malay population in Malaysia, as has been seen in Han Chinese in Taiwan. This indicates that the genetic association apparent in the incidence of CBZ-induced TEN/SJS is linked with the presence of HLA-B*1502, irrespective of racial origin. Screening of patients for this genetic marker can help to prevent the occurrence of TEN/SJS.
© 2011 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21244392     DOI: 10.1111/j.1365-4632.2010.04745.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  57 in total

1.  Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.

Authors:  S G Leckband; J R Kelsoe; H M Dunnenberger; A L George; E Tran; R Berger; D J Müller; M Whirl-Carrillo; K E Caudle; M Pirmohamed
Journal:  Clin Pharmacol Ther       Date:  2013-05-21       Impact factor: 6.875

Review 2.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

3.  Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population.

Authors:  C-C Chang; C-C Ng; C-L Too; S-E Choon; C-K Lee; W-H Chung; S H Hussein; K-S Lim; S Murad
Journal:  Pharmacogenomics J       Date:  2016-03-01       Impact factor: 3.550

Review 4.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

5.  Is universal HLA-B*15:02 screening a cost-effective option in an ethnically diverse population? A case study of Malaysia.

Authors:  H Y Chong; Z Mohamed; L L Tan; D B C Wu; F H Shabaruddin; M Dahlui; Y D Apalasamy; S R Snyder; M S Williams; J Hao; L H Cavallari; N Chaiyakunapruk
Journal:  Br J Dermatol       Date:  2017-09-21       Impact factor: 9.302

6.  Pharmacogenomics--how close/far are we to practising individualized medicine for children?

Authors:  Chor-Wing Sing; Ching-Lung Cheung; Ian C K Wong
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

7.  Upregulated RIP3 Expression Potentiates MLKL Phosphorylation-Mediated Programmed Necrosis in Toxic Epidermal Necrolysis.

Authors:  Sue Kyung Kim; Woo-Jung Kim; Jung-Ho Yoon; Jae-Hoon Ji; Michael J Morgan; Hyeseong Cho; You Chan Kim; You-Sun Kim
Journal:  J Invest Dermatol       Date:  2015-03-06       Impact factor: 8.551

8.  Drug hypersensitivity: pharmacogenetics and clinical syndromes.

Authors:  Elizabeth J Phillips; Wen-Hung Chung; Maja Mockenhaupt; Jean-Claude Roujeau; Simon A Mallal
Journal:  J Allergy Clin Immunol       Date:  2011-03       Impact factor: 10.793

9.  Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage.

Authors:  Rosa Chan; Chun-Yu Wei; Yuan-Tsong Chen; Leslie Z Benet
Journal:  AAPS J       Date:  2016-03-07       Impact factor: 4.009

10.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.